Berlin - Delayed Quote EUR

Iovance Biotherapeutics Inc (2LB.BE)

5.99

+0.04

+(0.67%)

As of 8:00:49 AM GMT+1. Market Open.

What's Wrong With Iovance Biotherapeutics Stock?

It was about a year ago that shares of Iovance Biotherapeutics (NASDAQ: IOVA) began to take off. Could this be a great buying opportunity for investors, or is the healthcare stock in danger of falling even lower this year? Why aren't investors more excited about Iovance?

Motley Fool yesterday

IOVA
Where Will Iovance Biotherapeutics Be in 5 Years?

Iovance Biotherapeutics (NASDAQ: IOVA), a small-cap biotech company, has an innovative approach to treating cancer that relies on harnessing patients' cancer-fighting capabilities. Iovance's shares are down by 71% in the past five years. Can the company turn things around and perform much better through the end of the decade?

Motley Fool 2 days ago

IOVA
Meet the Growth Stock That Could Soar 280%, According to Wall Street Analysts

If you're looking for an under-the-radar stock that could deliver enormous gains in a defined time frame, the biopharmaceutical industry has you covered. Hardly a week goes by without clinical trial results or a regulatory decision that produces dramatic market movements. One company Wall Street analysts have set their sights on, Iovance Biotherapeutics (NASDAQ: IOVA), is pioneering a new approach to treating cancer.

Motley Fool 4 days ago

IOVA
Insider Stock Buying Reaches US$48.3m On Iovance Biotherapeutics

Over the last year, a good number of insiders have significantly increased their holdings in Iovance Biotherapeutics...

Simply Wall St. 7 days ago

IOVA
Is Iovance Biotherapeutics (IOVA) Among Billionaire Joseph Edelman’s Long-Term Stock Picks?

We recently published a list of Billionaire Joseph Edelman’s Top 10 Long-Term Stock Picks. In this article, we are going to take a look at where Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) stands against other Billionaire Joseph Edelman’s long-term stock picks. Joseph Edelman is a renowned figure in the investment world, recognized for his expertise in biotechnology […]

Insider Monkey 11 days ago

IOVA
3 Stocks That Could Turn $1,000 Into $5,000 by 2030

A handful of bullish factors are converging at the right time in the right way for all three of these companies.

Motley Fool 12 days ago

AMZN

IOVA

ROKU
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SAN CARLOS, Calif., Jan. 17, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on January 16, 2025 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 224,550 shares of Iovance’s common stock to forty-one new,

GlobeNewswire 13 days ago

IOVA
3 Mid-Cap Stocks That Could Take Off in 2025

Mid-cap stocks represent companies valued at between $2 billion and $10 billion. If they give investors a reason to be bullish on their growth prospects or show that they're on the right path, these types of investments can double in value and be 10-baggers in the long run. Iovance Biotherapeutics has a market cap of $2.3 billion.

Motley Fool 22 days ago

VKTX

IOVA

CRSP
Exploring 3 High Growth Tech Stocks In The United States

Over the last 7 days, the United States market has experienced a 2.8% drop, yet it remains up by 24% over the past year with earnings forecasted to grow by 15% annually. In this context of fluctuating performance and promising growth prospects, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability in an evolving technological landscape.

Simply Wall St. 28 days ago

IOVA

FUFU

FUFUW
Why Iovance Biotherapeutics Stock Zoomed More Than 5% Higher Today

On the back of a glowing analyst recommendation, Iovance Biotherapeutics's (NASDAQ: IOVA) shares closed Thursday more than 5% higher in price. The entity delivering the good news was financial services company Stifel, whose analyst Benjamin Burnett tagged Iovance as its top stock pick in the biotech sector for 2025. Almost needless to say, Burnett reiterated his buy recommendation on the shares.

Motley Fool 28 days ago

IOVA
Why Iovance Biotherapeutics Inc. (IOVA) Is Skyrocketing

We recently published a list of 10 Firms End 2024 Stronger With Impressive Gains. In this article, we are going to take a look at where Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) stands against other firms end 2024 stronger with impressive gains. A lackluster trading persisted throughout the last day of the year, with Wall Street’s main […]

Insider Monkey 29 days ago

IOVA
If I Could Only Buy 3 Stocks in the Last Month of 2024, I'd Pick These

These windows of opportunity aren't likely to remain open for much longer.

Motley Fool last month

KO

UBER

IOVA
2 Growth Stocks That Could Rocket Higher in 2025: Are They Right for Your Portfolio?

The Food and Drug Administration (FDA) approved CRISPR Therapeutics' (NASDAQ: CRSP) first treatment last December, and its successful launch could push the stock much higher. Investment bank analysts also expect Iovance Biotherapeutics (NASDAQ: IOVA) to soar in 2025. Before chasing exciting price targets, though, it's important to remember that analysts who set lofty expectations can quietly adjust them downward if things don't work out.

Motley Fool last month

CRSP

IOVA
Prediction: This Stock Will Beat the Market in 2025

It hasn't been a great year for Iovance Biotherapeutics (NASDAQ: IOVA), an innovative mid-cap biotech company. Let's look deeper into how Iovance Biotherapeutics could pull that off. It is manufactured using patients' own TIL cells, which can identify and kill cancer cells.

Motley Fool last month

IOVA
3 Monster Stocks to Hold for the Next 10 Years

Just be ready to ride out some inevitable turbulence along the way.

Motley Fool last month

PANW

WOLF

IOVA
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is a favorite amongst institutional investors who own 63%

Key Insights Institutions' substantial holdings in Iovance Biotherapeutics implies that they have significant influence...

Simply Wall St. last month

IOVA
Is Iovance Biotherapeutics Stock a Millionaire Maker?

The biotech industry has been described as the Wild West of the stock market. While that level of success is only obvious in hindsight, Iovance Biotherapeutics (NASDAQ: IOVA) is an emerging industry leader with significant potential. This has been a milestone year for Iovance Biotherapeutics.

Motley Fool 2 months ago

IOVA
Iovance Biotherapeutics Announces the Promotion of Raj Puri, M.D., Ph.D. to Chief Regulatory Officer

SAN CARLOS, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that Raj Puri, M.D., Ph.D. has been promoted to the newly created role of Chief Regulatory Officer. Dr. Puri joined Iovance in March 2022 as Executive Vice President, Regulatory Strategy and Translational Medic

GlobeNewswire 2 months ago

IOVA
Got $1,500? Buy Iovance Biotherapeutics Now and Don't Look Back

As the rising star of cell therapy biotechs, Iovance Biotherapeutics (NASDAQ: IOVA) is a hot stock that's capturing a lot of attention, and for good reason. Today, Iovance has a trio of bullish drivers are the legs of the stock's investment thesis. First, Iovance's first cell therapy to be approved for sale, Amtagvi, is quickly finding its home in the market.

Motley Fool 2 months ago

IOVA
Iovance Biotherapeutics, Inc. (IOVA): Among the Most Promising Cancer Stocks According to Hedge Funds

We recently compiled a list of the 10 Most Promising Cancer Stocks According to Hedge Funds. In this article, we are going to take a look at where Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) stands against the other promising cancer stocks. According to the World Health Organization (WHO), cancer remains one of the leading causes of death globally, […]

Insider Monkey 2 months ago

IOVA

Performance Overview

Return	2LB.BE	S&P 500
YTD	-14.63%	+2.19%
1-Year	-20.92%	+22.56%
3-Year	-52.13%	+36.20%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Iovance Biotherapeutics Inc (2LB.BE)

What's Wrong With Iovance Biotherapeutics Stock?

Where Will Iovance Biotherapeutics Be in 5 Years?

Meet the Growth Stock That Could Soar 280%, According to Wall Street Analysts

Insider Stock Buying Reaches US$48.3m On Iovance Biotherapeutics

Is Iovance Biotherapeutics (IOVA) Among Billionaire Joseph Edelman’s Long-Term Stock Picks?

3 Stocks That Could Turn $1,000 Into $5,000 by 2030

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

3 Mid-Cap Stocks That Could Take Off in 2025

Exploring 3 High Growth Tech Stocks In The United States

Why Iovance Biotherapeutics Stock Zoomed More Than 5% Higher Today

Why Iovance Biotherapeutics Inc. (IOVA) Is Skyrocketing

If I Could Only Buy 3 Stocks in the Last Month of 2024, I'd Pick These

2 Growth Stocks That Could Rocket Higher in 2025: Are They Right for Your Portfolio?

Prediction: This Stock Will Beat the Market in 2025

3 Monster Stocks to Hold for the Next 10 Years

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is a favorite amongst institutional investors who own 63%

Is Iovance Biotherapeutics Stock a Millionaire Maker?

Iovance Biotherapeutics Announces the Promotion of Raj Puri, M.D., Ph.D. to Chief Regulatory Officer

Got $1,500? Buy Iovance Biotherapeutics Now and Don't Look Back

Iovance Biotherapeutics, Inc. (IOVA): Among the Most Promising Cancer Stocks According to Hedge Funds

Performance Overview